Other Vaccines - Thailand

Thailand

Highlights

Thailand's Other Vaccines market is expected to achieve a revenue of US$86.05m by 2024.
Furthermore, it is projected to witness a steady annual growth rate (CAGR 2024-2029) of 10.56%, ultimately leading to a market volume of US$142.20m by 2029.
When compared globally, United States is forecasted to generate the highest revenue in this market, with US$24.73bn in 2024.
Thailand's increasing focus on public health is driving the demand for other vaccines in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Thailand has been growing steadily in recent years.

Customer preferences: Thailand has a relatively high vaccination rate, with a majority of the population receiving vaccinations against common diseases such as measles, polio, and hepatitis B. However, there has been an increasing demand for other vaccines, particularly those related to travel and lifestyle. This is due to the growing popularity of international travel and the rise of lifestyle diseases such as HPV and pneumococcal disease.

Trends in the market: The Other Vaccines market in Thailand has been growing due to the increasing demand for travel and lifestyle vaccines. The market has seen a rise in the number of private clinics offering these vaccines, as well as an increase in online bookings. In addition, there has been a growing trend towards combination vaccines, which offer protection against multiple diseases in a single shot. This has been particularly popular among parents looking to vaccinate their children against multiple diseases at once.

Local special circumstances: Thailand has a large tourism industry, with millions of tourists visiting the country each year. This has led to an increase in demand for travel vaccines, particularly for diseases such as yellow fever, typhoid, and rabies. In addition, the country has a high incidence of dengue fever, which has led to an increased demand for vaccines against the disease.

Underlying macroeconomic factors: Thailand has a growing middle class, which has led to an increase in demand for healthcare services, including vaccinations. In addition, the government has been promoting healthcare tourism, which has led to an increase in the number of medical tourists visiting the country for vaccinations. The government has also been investing in healthcare infrastructure, which has led to an increase in the number of private clinics offering vaccinations. Finally, the country has a relatively low cost of living, which has made it an attractive destination for medical tourism.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.